Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026)
Verastem (VSTM) recorded quarterly Total Non-Current Liabilities of $146.0 million in Q1 2026, down 4.93% quarter-over-quarter from $153.6 million in Q4 2025, and up 33.5% on a YoY basis from $109.4 million in Q1 2025.
Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Verastem's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 33.5% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $146.0 million (up 33.5% YoY), while the FY2025 annual figure was $153.6 million, up 112.65% from the prior year.
- Total Non-Current Liabilities was $146.0 million for Q1 2026 at Verastem, down from $153.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $153.6 million in Q4 2025 to a low of $68.0 million in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $114.7 million across 4 years, with a median of $126.7 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities fell 5.21% in 2024, then soared 112.65% in 2025.
- A 4-year view of Total Non-Current Liabilities shows it stood at $71.8 million in 2023, then advanced by 0.65% to $72.2 million in 2024, then jumped by 112.65% to $153.6 million in 2025, then retreated by 4.93% to $146.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $146.0 million (Q1 2026), $153.6 million (Q4 2025), and $144.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | 146.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 153.60 Mn |
| Sep 30, 2025 | 144.09 Mn |
| Jun 30, 2025 | 152.66 Mn |
| Mar 31, 2025 | 109.39 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Sep 30, 2024 | 68.02 Mn |
| Sep 30, 2023 | 71.76 Mn |
| Jun 30, 2020 | 83.29 Mn |
| Mar 31, 2020 | 84.30 Mn |
| Dec 31, 2019 | 137.00 Mn |
| Sep 30, 2019 | 170.21 Mn |
| Jun 30, 2019 | 168.73 Mn |
| Mar 31, 2019 | 154.41 Mn |
| Dec 31, 2018 | 151.81 Mn |
| Sep 30, 2018 | 74.98 Mn |
| Jun 30, 2018 | 45.65 Mn |
| Mar 31, 2018 | 29.76 Mn |
| Dec 31, 2017 | 31.96 Mn |
| Sep 30, 2017 | 21.95 Mn |